Management of bacterial meningitis
Reading File
Finding Sources
Searching PubMed
"bacterial meningitis"[MeSH Terms] AND "management"[tiab]
Searching the Web
bacterial meningitis management guidelines 2024 2025
Finding Sources
Searching PubMed
"bacterial meningitis" AND treatment
Reading Web Page
bacterial meningitis management antibiotics dexamethasone
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full management guide.
Management of Bacterial Meningitis
Bacterial meningitis is a neurologic emergency with mortality ~15% even with treatment. Outcome depends critically on speed of diagnosis and initiation of therapy.
1. Initial Assessment & Diagnosis
Clinical Presentation
The classic triad — fever, headache, nuchal rigidity — is present in ~85% of adult patients. Additional features include:
- Photophobia, phonophobia, nausea/vomiting
- Altered consciousness (~30%), seizures (~30%)
- Cranial nerve palsies and focal deficits (10–20%)
- Kernig sign (resistance to knee extension with hip at 90°) and Brudzinski sign (involuntary knee flexion on passive neck flexion): low sensitivity (<12%) but high specificity
- Petechial/purpuric rash on extremities → strongly suggests N. meningitidis
- Shock + purpura + DIC → Waterhouse-Friderichsen syndrome (bilateral adrenal hemorrhage in meningococcemia)
Special populations:
- Neonates: poor feeding, irritability, temperature instability, bulging fontanelle, seizures; nuchal rigidity unreliable <1 year
- Elderly: insidious onset, variable meningeal signs, altered mental status without fever
- Immunocompromised: altered mental status may be the only finding
When to Obtain CT Before LP
Perform CT head first if the patient has:
- Papilledema
- New-onset seizures
- Focal neurologic deficits
- Decreased level of consciousness
- → If CT is needed, draw blood cultures and start antibiotics immediately — do not delay treatment for imaging
CSF Findings
| Parameter | Bacterial Meningitis | Viral Meningitis |
|---|---|---|
| Opening pressure (mmH₂O) | >180 | Normal or elevated |
| WBC (cells/mm³) | 1,000–10,000 (median 1,195) | <300 |
| Neutrophils | >80% | <20% |
| Glucose (mg/dL) | <40 (or <40% serum glucose) | >40 |
| Protein (mg/dL) | 100–500 | Normal or slightly elevated |
| Gram stain positive | 60–90% | Negative |
| Culture positive | 70–85% | ~50% |
— Textbook of Family Medicine 9e; ROSEN's Emergency Medicine
2. Common Pathogens by Age
| Age | Predominant Pathogens |
|---|---|
| 0–1 month | Group B streptococcus, E. coli, Listeria monocytogenes, S. pneumoniae |
| 1–3 months | Group B strep, Listeria, S. pneumoniae, N. meningitidis, H. influenzae |
| 3 months–18 years | S. pneumoniae, N. meningitidis, H. influenzae |
| 18–50 years | S. pneumoniae, N. meningitidis |
| >50 years | S. pneumoniae (~70%), Listeria, gram-negative bacilli |
| Post-neurosurgery/trauma | Coagulase-negative staphylococci, S. aureus, Cutibacterium acnes, Pseudomonas aeruginosa |
— Textbook of Family Medicine 9e; Goldman-Cecil Medicine
3. Empirical Antibiotic Therapy
Start within 1 hour of clinical suspicion. Never delay antibiotics to wait for LP results if CT is required.
Standard Empirical Regimen (Community-Acquired Adults)
| Component | Drug | Dose |
|---|---|---|
| Coverage for pneumococcus (resistant strains) | Vancomycin | 15–20 mg/kg IV q8h |
| Coverage for gram-negatives & pneumococcus | Ceftriaxone | 2 g IV q12h |
| (or) | Cefotaxime | 3 g IV q6h |
Add ampicillin 2 g IV q4h when Listeria coverage is needed:
- Adults >50 years
- Immunocompromised, pregnant, alcoholic, diabetic
- Signs of brainstem involvement
- Gram-positive rods on CSF Gram stain
Consider gentamicin (synergistically with ampicillin) in confirmed/suspected Listeria meningitis — use cautiously if renal impairment.
Neonates
- Cefotaxime (not ceftriaxone — displaces bilirubin from albumin in hyperbilirubinemia) + ampicillin
- Ampicillin: 100 mg/kg/dose q8h (days 0–7); 75 mg/kg/dose (days 8–28)
Healthcare-Associated / Post-Neurosurgical Meningitis
- Cefepime 2 g IV q8h (instead of ceftriaxone) + vancomycin
- Covers resistant organisms including Pseudomonas
- For P. aeruginosa: ceftazidime or cefepime; alternatives include aztreonam, ciprofloxacin, meropenem ± aminoglycoside
Allergy / Resistant Strains
- Cephalosporin allergy: meropenem or chloramphenicol
- Highly penicillin/cephalosporin-resistant pneumococcus: vancomycin + rifampin IV; or linezolid 600 mg q12h + vancomycin; or moxifloxacin 400 mg OD + vancomycin
— ROSEN's Emergency Medicine; Textbook of Family Medicine 9e; Goldman-Cecil Medicine
4. Targeted Therapy by Organism (After Culture/Sensitivity)
| Organism | First-Line | Alternatives |
|---|---|---|
| S. pneumoniae (susceptible) | Ceftriaxone or cefotaxime | Meropenem, fluoroquinolone |
| S. pneumoniae (resistant) | Vancomycin + ceftriaxone | Vancomycin + rifampin, linezolid |
| N. meningitidis | 3rd-generation cephalosporin | Penicillin G, ampicillin, chloramphenicol, fluoroquinolone |
| L. monocytogenes | Ampicillin (± gentamicin) | TMP-SMX, meropenem |
| H. influenzae | 3rd-generation cephalosporin | Chloramphenicol, cefepime, meropenem, fluoroquinolone |
| E. coli / gram-negative bacilli | 3rd-generation cephalosporin | Cefepime, meropenem, aztreonam, fluoroquinolone |
| S. agalactiae (Group B) | Ampicillin or penicillin G | 3rd-generation cephalosporin |
— Textbook of Family Medicine 9e
5. Adjunctive Corticosteroid Therapy
Dexamethasone is a critical adjunct in adult bacterial meningitis.
- Dose: 0.15 mg/kg (up to 10 mg) IV q6h × 4 days
- Timing: Administer with or 20 minutes BEFORE the first antibiotic dose for maximum efficacy
- Benefit:
- Reduces mortality in pneumococcal meningitis
- Reduces hearing loss in H. influenzae meningitis
- Benefit is mainly demonstrated in high-income countries (better access to specialist care)
- Caution: May reduce CSF vancomycin penetration (if given with vancomycin for resistant pneumococcus, consider rifampin addition)
- Discontinue if Listeria meningitis is confirmed — steroids increase adverse outcomes in Listeria CNS infection
- No role for empiric corticosteroids in neonatal meningitis
— ROSEN's Emergency Medicine; Goldman-Cecil Medicine
6. Supportive & ICU Management
Fluid Management
- Give normal daily fluid requirements + volume deficit correction
- Avoid excessive fluid — can worsen cerebral edema and herniation
- Restrict fluid if SIADH (hyponatremia) develops; monitor serum sodium closely
Raised Intracranial Pressure (ICP)
- Head of bed elevation (30°)
- Endotracheal intubation if severely elevated ICP
- Mannitol or hypertonic saline (osmotherapy)
- Maintain eucapnia on ventilator (avoid aggressive hyperventilation except as bridge)
- Avoid hypotension and hypoxia
Seizure Control
- Prompt treatment with benzodiazepines (first-line), phenytoin, or levetiracetam
- Particularly important in neonates (seizures in 40%)
Monitoring
- Neurological observations (GCS, pupils, focal signs)
- Watch for cerebral venous thrombosis (~1% of cases): presents with new seizures, focal deficits, altered sensorium
- Coagulation screen (PT, PTT, platelets) for DIC in severe meningococcemia
7. Duration of Antibiotic Therapy
| Organism | Duration |
|---|---|
| N. meningitidis | 5–7 days |
| H. influenzae | 7 days |
| S. pneumoniae | 10–14 days |
| Listeria monocytogenes | 21 days |
| Gram-negative bacilli (including E. coli) | 21 days |
| Healthcare-associated / Pseudomonas | ≥3 weeks (or 2 weeks after first sterile CSF culture) |
8. Chemoprophylaxis for Close Contacts
Meningococcal meningitis: ciprofloxacin 500 mg PO single dose (adults) or rifampin 600 mg PO q12h × 2 days → for household contacts, healthcare workers with unprotected mucosal exposure.
Group B streptococcus (neonatal prevention): intrapartum IV penicillin G (or ampicillin) for colonized mothers — highly effective for early-onset disease.
9. Complications
| Complication | Notes |
|---|---|
| Hearing loss | Most common in H. influenzae and pneumococcal meningitis; reduced by dexamethasone |
| Hydrocephalus | Due to CSF outflow obstruction; may require surgical drainage |
| Cerebral infarction | From vasculitis/venous thrombosis; assess with MRI |
| Waterhouse-Friderichsen syndrome | Bilateral adrenal hemorrhage in meningococcemia; DIC, cardiovascular collapse |
| Subdural empyema | Requires neurosurgical drainage |
| Residual neurologic deficits | Highest in pneumococcal meningitis |
10. Key Recent Evidence (PubMed, 2023–2026)
- Bulaeva & Derber, Med Clin North Am 2025 (PMID 40185548): Contemporary review reinforcing standard management framework
- Xu et al., Virulence 2024 (PMID 39192572): Advances in pathogenesis and treatment of pneumococcal meningitis, including emerging targets for adjunctive therapy
- WHO Guidelines on Meningitis 2025 (published April 2025): Reaffirms ceftriaxone/cefotaxime as universal empiric backbone; antibiotics must be started within 1 hour of suspicion
⚠️ Note: WHO 2025 guidelines are the most current international standard. For TB meningitis, a separate 4-drug RHEZ regimen applies (isoniazid + rifampin + pyrazinamide + ethambutol).
Sources: ROSEN's Emergency Medicine (9e), Goldman-Cecil Medicine, Textbook of Family Medicine (9e), Bradley & Daroff's Neurology in Clinical Practice, WHO Meningitis Guidelines 2025.
This is a shared conversation. Sign in to Orris to start your own chat.